drugset / Trial / NCT06116734
Lapelga vs Gastrofil
Phase 3
Unknown
74 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Apobiologix. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is examining one-time injection of biosimilar pegfilgrastim compared with multiple injection biosimilar filgrastim post autologous hematopoietic stem cell transplantation. Study aims to compare biosimilar pegfilgrastim - LaPelga and biosimilar filgrastim -Gastrofil to see if they are similar in efficacy in terms of neutrophil engraftment, limited adverse effects, and more convenience to our patients, with potential cost savings.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-11-01
- Completion
- 2025-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | filgrastim | Protein / enzyme biologic | — | Subcutaneous |